ART Advanced Research Technologies to be Present at the Annual Meeting of the Radiological Society of North America (RSNA) in Ch

MONTREAL, CANADA (TSX: ARA), a Canadian medical device company and a leader in optical molecular imaging products for the healthcare and pharmaceutical industries, is pleased to announce its participation at the 93rd annual meeting of the Radiological Society of North America (RSNA) being held at McCormick Place in Chicago, from November 25 to 30, 2007. ART will showcase the SoftScan® system, an optical medical imaging device designed to improve the diagnosis and treatment monitoring of breast cancer, at its booth (#4074) located in the South Building Exhibit Hall of McCormick Place.

"ART believes that there is a large market opportunity for the SoftScan breast imaging device, to address 'blind spots' offered by other imaging modalities such as mammography," said Sebastien Gignac, ART's President and CEO. "At the 2007 RSNA, we will be showing how SoftScan is doing this, through recent clinical results obtained for indications in diagnostic imaging, as well as for treatment monitoring. In particular, the treatment monitoring application currently under investigation in study sites in Canada and the United States, offers a clear value proposition to clinics, radiologists and third-party payers, helping to ensure effective treatment and reduce chemotherapy drug costs," added Mr. Gignac.

Following the regulatory approvals obtained for the commercialization of the device in the course of the past year, the device is to be sold in Canada, Europe and other markets outside the United States, as well as globally for investigative use in drug development research settings.

About the SoftScan® system

The SoftScan® optical breast imaging system has been designed first as a complementary diagnostic tool to mammography, with ultimate uses in the detection and treatment monitoring of breast cancer. Its non-invasive, painless approach uses time-domain optical imaging technology, which may allow clinicians to better locate and characterize breast tumors as benign or malignant and could provide faster assessment of therapeutic effectiveness. Unlike mammography whose use must be strictly limited, the SoftScan system emits no radiation and can be safely used as often as needed to monitor patients. The device was created and developed by ART Advanced Research Technologies Inc., and has obtained regulatory approvals for its commercialization in Canada and in Europe.

About ART

ART Advanced Research Technologies Inc. is a leader in molecular imaging products for the healthcare and pharmaceutical industries. ART has developed products in medical imaging, medical diagnostics, disease research, and drug discovery with the goal of bringing new and better treatments to patients faster. The Optix® optical molecular imaging system, designed for monitoring physiological changes in living systems at the preclinical study phases of new drugs, is distributed directly by ART in North America and Europe and is used by industry and academic leaders worldwide. The SoftScan® optical breast imaging device is designed to improve the diagnosis and treatment of breast cancer. ART is commercializing the SoftScan optical medical imaging device via a global strategic alliance with GE Healthcare, a world leader in mammography and imaging. Finally, the Fenestra® line of molecular imaging contrast products provide image enhancement for a wide range of preclinical Micro CT applications allowing scientists to see greater detail in their imaging studies, with potential extension into other major imaging modalities. The distribution of the Fenestra line of imaging contrast agents is made through GE Healthcare Bio-Science KK in Japan and is sold directly by the Company in the rest of the world. ART's shares are listed on the TSX under the ticker symbol ARA. For more information on ART, visit our website at www.art.ca .

This press release may contain forward-looking statements subject to risks and uncertainties that would cause actual events to differ materially from expectations. These risks and uncertainties are described in the most recent Annual Information Form and the financial statements for the year ended December 31, 2006, available on SEDAR (www.sedar.com).

Contacts: ART Advanced Research Technologies Inc. Jacques Bedard Chief Financial Officer 514-832-0777 [e-mail] www.art.ca